Pfizer (PFE)
27.03
-0.18 (-0.68%)
NYSE · Last Trade: Oct 2nd, 2:12 PM EDT
Detailed Quote
| Previous Close | 27.21 |
|---|---|
| Open | 26.93 |
| Bid | 27.02 |
| Ask | 27.03 |
| Day's Range | 26.62 - 27.17 |
| 52 Week Range | 20.92 - 30.43 |
| Volume | 49,262,995 |
| Market Cap | 151.52B |
| PE Ratio (TTM) | 14.38 |
| EPS (TTM) | 1.9 |
| Dividend & Yield | 1.720 (6.36%) |
| 1 Month Average Volume | 56,892,127 |
Chart
About Pfizer (PFE)
Pfizer is a global biopharmaceutical company that develops and manufactures innovative medicines and vaccines to improve health outcomes for people around the world. Renowned for its extensive research and development efforts, Pfizer focuses on various therapeutic areas including vaccines, oncology, immunology, cardiology, endocrinology, and rare diseases. The company is committed to addressing significant health challenges through the discovery of new treatments, leveraging cutting-edge science and technology. Pfizer also emphasizes partnerships and collaborations to expand its capabilities and enhance access to healthcare solutions. Read More
News & Press Releases
Let's have a look at what is happening on the US markets on Thursday. Below you can find the most active S&P500 stocks in today's session.
Via Chartmill · October 2, 2025
The uncertainty about U.S. pharmaceutical tariffs shouldn't be as worrisome for AstraZeneca now.
Via The Motley Fool · October 2, 2025
Shares of lab services company Charles River Laboratories (NYSE:CRL)
jumped 1.9% in the morning session after Barclays upgraded the company to Overweight from Equal-Weight and raised its price target.
Via StockStory · October 2, 2025
Pfizer Stock Hits 9-Month High As Analysts Dismiss Trump Drug Deal’s Financial Risk; Retail Stays ‘Extremely Bullish’stocktwits.com
Via Stocktwits · October 1, 2025
London, UK – October 2, 2025 – In a monumental stride for biotechnology and medicine, generative artificial intelligence (AI) has achieved a scientific breakthrough, demonstrating an unprecedented ability to design synthetic proteins for genome editing that not only match but significantly outperform their naturally occurring counterparts. This pivotal development, highlighted by recent research, signals a [...]
Via TokenRing AI · October 2, 2025
The pharmaceutical industry is on the cusp of a profound transformation, driven by the accelerating integration of Artificial Intelligence (AI). Projections indicate that the global AI in pharmaceutical market is set to explode, reaching an astounding valuation of over $65 billion by 2033. This represents not merely a significant market expansion but a fundamental shift [...]
Via TokenRing AI · October 2, 2025
Pfizer has an attractive 7.2% dividend yield, but there are some pros and cons you need to understand before you buy it.
Via The Motley Fool · October 2, 2025
These dividend stocks offer the potential to produce big-time income streams.
Via The Motley Fool · October 2, 2025
A new expansion project and a win for a peer pharmaceutical company were attracting investors to the shares.
Via The Motley Fool · October 1, 2025
The company's push deeper into a hot new technology, plus good news from a top collaborator, put the shine on its equity.
Via The Motley Fool · October 1, 2025
Washington D.C., October 1, 2025 – The United States federal government has officially entered a shutdown today, marking the first such funding lapse in nearly seven years and sending immediate ripples of uncertainty across global financial markets. The inability of Congress to pass appropriations legislation for the 2026 fiscal year
Via MarketMinute · October 1, 2025
London, UK – October 1, 2025 – The UK's benchmark FTSE 100 index has achieved an unprecedented milestone today, surging to a new all-time high. The robust performance was largely propelled by a significant rally in pharmaceutical stocks, alongside a strengthening British Pound, signaling renewed investor confidence in the UK market's resilience
Via MarketMinute · October 1, 2025
High-yield Dividend Achievers, such as United Parcel Service, Verizon, and Pfizer, offer attractive entry points in October for income investors.
Via MarketBeat · October 1, 2025
London's financial markets are buzzing today, October 1, 2025, as a robust rally in the pharmaceuticals sector has propelled the FTSE 100 to a new record high. This significant surge, primarily fueled by a landmark development in US drug pricing policy, underscores the critical influence of healthcare giants on the
Via MarketMinute · October 1, 2025
New York, NY – October 1, 2025 – In a surprising turn of events on Wall Street today, the healthcare sector emerged as the undisputed leader, shrugging off the dual anxieties of a U.S. government shutdown and a disappointing jobs report. As investors sought refuge in defensive plays and reacted to
Via MarketMinute · October 1, 2025
A bullish analyst note added to the generally good sentiment on the company.
Via The Motley Fool · October 1, 2025
Shares of clinical research company IQVIA (NYSE: IQV)
jumped 6.3% in the afternoon session after the company, in partnership with GSK, announced a major update to its Vaccine Track data tool for tracking adult immunization activity in the U.S. The enhancement adds local-level data for 387 metro areas and expands the dataset to a full decade of information. This update is designed to help public health organizations and providers identify immunization gaps and improve their community outreach efforts. The collaboration with pharmaceutical giant GSK underscores IQVIA's role in providing critical health data analytics. This development occurs within a positive industry context, as the broader biologics contract research organization market, a key sector for IQVIA, is projected to experience strong growth due to increased outsourcing of R&D by large pharmaceutical firms.
Via StockStory · October 1, 2025
Shares of diversified science and technology company Danaher (NYSE:DHR)
jumped 6.6% in the afternoon session after its subsidiary, Leica Biosystems, announced the launch of new artificial intelligence (AI)-powered digital pathology solutions.
Via StockStory · October 1, 2025
Shares of pharmaceutical company AbbVie (NYSE:ABBV) jumped 5.2% in the afternoon session after the company submitted a biologics license application (BLA) to the U.S. Food and Drug Administration (FDA) for its drug candidate pivekimab sunirine. The company is developing the molecule as a potential treatment for blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare and highly aggressive blood cancer, as well as acute myeloid leukemia (AML). Investor optimism was further bolstered by AbbVie's announcement of a $70 million expansion of its Bioresearch Center in Massachusetts to increase its U.S. biologics manufacturing and R&D capabilities. This move is part of a larger investment to strengthen domestic operations, potentially shielding the company from pharmaceutical tariffs. The positive news, which followed the stock reaching an all-time high on the previous day, appeared to outweigh a downgrade from HSBC to 'Hold' from 'Buy'.
Via StockStory · October 1, 2025
Shares of global pharmaceutical company Pfizer (NYSE:PFE)
jumped 7.2% in the afternoon session after the company announced a landmark agreement with the U.S. government aimed at lowering prescription drug prices for American patients.
Via StockStory · October 1, 2025
Shares of global pharmaceutical company Eli Lilly (NYSE:LLY)
jumped 8.6% in the afternoon session after the stock's positive momentum continued as the White House revealed plans to launch a website for consumers to purchase drugs from manufacturers at a discount, providing clarity for the pharmaceutical industry on future pricing policies. The positive sentiment was bolstered by news that competitor Pfizer had already secured a deal to lower some of its U.S. drug prices. Following this, Eli Lilly confirmed it is in "active discussions with the administration to further expand patient access." This development has eased investor concerns about potential government-imposed price controls, which had created uncertainty for the sector. The prospect of reaching favorable agreements is now seen as an opportunity for major drugmakers, leading to a rally across the industry.
Via StockStory · October 1, 2025
Shares of global pharmaceutical company Merck (NYSE:MRK)
jumped 7.7% in the afternoon session after the Trump administration announced a new program to sell drugs directly to consumers.
Via StockStory · October 1, 2025
Shares of life sciences company Thermo Fisher (NYSE:TMO)
jumped 9% in the afternoon session after the company secured a major manufacturing agreement with biotechnology firm Vaxcyte and announced a new AI-focused partnership.
Via StockStory · October 1, 2025
Shares of biotech company Amgen (NASDAQ:AMGN)
jumped 6.4% in the afternoon session after the company announced a $650 million investment to expand its US manufacturing network. The investment is aimed at increasing drug production at its biologics facility in Juncos and is expected to create nearly 750 new jobs, including highly skilled manufacturing roles. According to CEO Robert A. Bradway, the expansion highlights Amgen's commitment to US biomanufacturing and strengthening its global supply chain. In other news, the company reached a settlement with Biocon Biologics. The agreement resolves pending patent litigation and allows Biocon to launch biosimilar versions of Amgen's drug, denosumab, in the U.S. starting October 1, 2025.
Via StockStory · October 1, 2025